World Clinical Biomarkers & CDx Summit 

  • -
Boston, MA
United States

12th World CB and CDx

September 28-29, 2022

Boston, MA

*In Person

Event Overview

Marrying Complex Biomarker Validation & CDx Development for Supercharged Precision Oncology Pipeline Commercialization

The 12th World Clinical Biomarkers & CDx Summit returns at a crucial time for the entire precision & targeted drug development industry. Spurred on by a number of recent exciting biomarker-driven therapy and CDx approvals by the FDA, including Eli Lilly’s Verzenio, J&J’s Amivantamab & Takeda’s Mobocertinib, the race to market is becoming ever fiercer to deliver the next-generation of safer & more effective therapies for defined patient populations.

Returning in-person for the first time in three years, hear the latest insights, case studies and technologies enhancing your predictive biomarker discovery, to support next generation CDx development, informed clinical decisions, regulatory approval & a robust go-to market strategy for a breakthrough therapy.

Across 2-days & 3 distinct tracks, this is your only end-to-end biomarker-driven & diagnostic enabled drug development summit, led by 70+ industry leaders triumphing and overcoming challenges to predictive biomarker development and commercialization.

NanoString Activities

Program Partner Presentation

TECH SLAM: New Exploratory Biomarker Technology

  • Date/time: Wednesday, September 28 | 4:20 PM ET
  • Speaker: Eric Miller, Global Technical Specialist, CosMx SMI, NanoString Technologies

Panel Discussion: Tissue is the Issue

Track: Biomarker Discovery & Translational Development | Tools & Techniques Driving Efficiencies in Biomarker Discovery

Date/time: Thursday, September 29 | 10:40 AM ET
Speakers: Espy Anguiano, Scientific Market Development, BioPharma; Joshua Rusbuldt, MA, Scientist of R&D, Janssen Pharmaceuticals